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Abstract
Importance—Mesenchymal stem cells have the ability to differentiate into osteoblasts,
chondrocytes and adipocytes. Along with differentiation, MSCs can modulate inflammation, home
to damaged tissues and secret bioactive molecules. These properties can be enhanced through
genetic-modification that would combine the best of both cell and gene therapy fields to treat
monogenic and multigenic diseases.
Areas covered—A review of the findings demonstrating the immunomodulation, homing and
paracrine activities of MSCs followed by a summary of the current research utilizing MSCs as a
vector for gene therapy, focusing on skeletal disorders, but also cardiovascular disease, ischemic
damage and cancer.
What the reader will gain—MSCs are a possible therapeutic for many diseases, especially
those related to the musculoskeletal system, as a standalone treatment, or in combination with
factors that enhance the abilities of these cells to migrate, survive or promote healing through anti-
inflammatory and immunomodulatory effects, differentiation, angiogenesis, delivery of cytolytic
or anabolic agents.
Take home message—Genetically-modified MSCs are a promising area of research that
would be improved by focusing on the biology of MSCs that could lead to identification of the
natural and engrafting MSC-niche and a consensus on how to isolate and expand MSCs for
therapeutic purposes.
Keywords
mesenchymal stem cell; gene therapy; genetic modifications; genetic engineering;
immunomodulatory; paracrine effects; skeletal disorders
1. Introduction
The discovery of adult stem cells incited expectations for novel therapies to multiple
diseases and disorders. Multipotent stromal cells, or mesenchymal stem cells (MSC), are
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adult stem cells that can differentiate into cells of the mesoderm-lineage, including
osteoblasts, chondrocytes and adipocytes [1,2]. The field of regenerative medicine developed
to utilize the intrinsic multipotentiality of these cells to overcome failed, faulty or ineffective
repair processes. The potential usefulness of MSCs in gene therapy was quickly recognized
during their characterization. Along with differentiation, MSCs have been found to be both
hypoimmunogenic and immunomodulatory, can home to damaged tissues and depend on
secretion of bioactive molecules to initiate healing in repair processes. These characteristics
suggest that genetically-modified MSCs could combine the best of both cell and gene
therapy fields to treat diverse diseases from cancer to cardiovascular or skeletal diseases.
Despite successes in animal models, the use of gene therapy in humans has remained
unfulfilled. The few clinical trials involving delivery of genes to humans have seen only
limited success with severe drawbacks, which highlight the challenges that this emerging
field is still facing. Delivery of genes is achieved using one of several types of viral vectors
and even these modified vectors can lead to toxicity and inflammatory responses. In one
clinical study aimed to evaluate safety and efficacy of gene therapy in subjects with enzyme
ornithine transcarboxylase deficiency, a patient died of a severe immune response likely
caused by the viral vector used as a delivery mechanism [3]. Work is ongoing to alter viral
vectors to make them safe. Other non-viral techniques are also being pursued, such as the
use of liposomes or nanoparticles to help cell uptake of naked or unmodified plasmid DNA.
Targeting the DNA for genomic incorporation also remains an issue. In clinical studies
using bone marrow (BM) cells to deliver interleukin-2 to X-linked severe combined
immunodeficiency patients in Europe, despite promising results, some patients developed
leukemia-like symptoms leading to death likely due to the insertion of the IL-2 gene near an
oncogene [4]. Based on these fatalities, in April of 2003 the FDA banned gene therapy trials
using retroviral vectors in blood stem cells. Current research is focusing on targeting gene
insertion into “safe harbor” areas of the genome specifically in MSCs [5]. Other
complications in the use of gene therapy include lack of tissue specific targeting, control
over timing and expression level of the additive gene as well as the elicitation of an
undesired immune response. All these issues could be addressed by using improved gene
delivery vector systems with an immune-modulating, engraftable, highly plastic, yet
naturally occurring, injury-seeking stem cell such as MSCs.
MSCs are rare, non-hematopoietic progenitor cells first isolated from BM mainly based on
their ability to adhere to plastic culture dishes. Freidenstein et al., in characterizing these
cells found them to be clonogenic in culture and multipotent for stromal precursors [6].
Though mainly found in BM and adipose tissue, examples of isolation from peripheral
blood, umbilical cord blood, synovial membranes, deciduous teeth, amniotic fluid and
perivascular regions exist, leaving open the question of the natural niche for MSCs [7].
Pericytes are cells that surround blood vessels throughout the body and recent work has
compared the phenotype of pericytes and MSCs and found that MSCs express pericyte
markers [8]. It is possible then that all MSCs are pericytes and the natural niche is
perivascular, which would allow MSCs easy access to cytokines and chemokines and a
means to migrate to injured tissue, though whether these are truly the same cell is still up for
debate. The osteo-, chondro- and adipo-genic ability of MSCs has since been established and
examples of differentiation into cells such as, cardiomyocytes, neurons and hepatocytes have
been described [2,9–11]. The ability of MSC to differentiate into non-mesodermal lineages
remains controversial and could be attributable to a lack of homogeneity within isolated
MSC populations, or due to disparate isolation and expansion techniques. In fact, a specific,
true multipotent MSC population has yet to be clearly defined. Currently the International
Society for Cell Therapy defines human multipotent mesenchymal stromal cells as plastic
adhering cultured cells that express CD105, CD73 and CD90, and lack expression of CD45,
CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface molecules, while
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maintaining the ability to differentiate into osteoblasts, adipocytes and chondrocytes in
vitro [12]. These requirements are not completely specific and do not extend to rodent and
other animal sources of MSCs, in which a significant portion of the basic research is being
performed, thus further identification of markers is required.
MSCs have several favorable qualities that signify their usefulness as a source of therapeutic
treatments for multiple disorders. Besides the ease of isolation and expansion in culture and
their capacity to differentiate into multiple lineages, MSCs: have key interactions with the
immune system; have been shown to migrate to sites of injury; generate strong paracrine
effects with surface and shed molecules.
Transplanted MSCs have been shown to home to sites of damaged tissue. Bone fractures,
infarcted heart muscle, rat ischemic brain and renal injury are all sites of localization of
transplanted MSCs in animal models [13–16]. The fact that MSCs can be isolated from
peripheral blood and can be found in increased numbers under stress of total body
irradiation or hypoxia implies that MSCs are part of the innate healing response involving a
natural trafficking signal that can be utilized by transplanted MSCs [17,18]. MSCs express an
assortment of chemokine receptors that allow for their migration in response to the
chemokine-attractive gradients generated by the inflamed injured site. The functional
chemokine receptors expressed by MSCs include CCR1, CCR7, CCR9, CXCR3, CXCR4,
CXCR5 and CX3CR1 [19]. The CXCR4 receptor and its single, specific chemokine, SDF1/
CXCL12 has an important role in the regulation of hematopoietic stem cells (HSC) and
other stem cell trafficking, along with a part in controlling the metastasis of several types of
cancer [20,21]. This signaling axis has been shown to regulate MSC localization to damaged
heart tissue in a rat model of myocardial infarction and to fractured mouse tibias [13,15]. Both
in vitro and in vivo experiments with MSCs overexpressing CXCR4 have shown increased
migration, localization and healing in the case of transplantation into mice suffering
coronary occlusion-reperfusion injury [22,23]. SDF1 expression is upregulated in rodent
hearts following myocardial infarction and this led to an increase in the number of MSCs
recruited to the injured tissue [24,25]. However, Ip et al. showed that inhibition of CXCR4 in
MSC had no effect on MSC migration to ischemic myocardium, but instead was dependent
on integrin β1 [26]. Similarly, MSC homing to bone was improved with ectopic expression
of integrin α4 and ts association with integrin β1 in mice [27]. The chemokine receptor CCR7
has been associated with MSC localization to CCL2- expressing skin wound sites [28]. The
chemokine CCL2 (MCP-1) is also produced at sites of inflammation and reported to be
critical for recruiting MSCs expressing its receptor CCR2 [29]. The innate ability of MSCs to
target sites of injury and damage and the determination of the mechanisms involved will
have important implications for the therapeutic use of MSCs.
There are an increasing number of studies showing MSC-dependent improvement of
damaged tissues without a significant contribution of engrafted and differentiated cells. The
mechanism for this is still under investigation, but likely depends on paracrine-mediated
effects of MSCs. In response to injury, MSCs in culture secrete a large number of cytokines,
chemokines and other trophic factors [30,31]. Improvement or protective effects of MSCs
despite low levels of engraftment within hepatotoxin damaged liver and mouse myocardial
infarction model led the authors to test MSC conditioned media in their models, which
reproduced the results of intact MSC transplant [32,33]. The paracrine-mediated effects of
MSC can be seen in another of MSCs beneficial properties, immunomodulation.
MSCs were first isolated from BM, a key site of hematopoiesis in which MSCs are now
thought to play a role. HSCs require stromal supporting cells for proper differentiation and
for the maintenance of the quiescent state within the endosteal niche of the BM and both
supporting functions can be carried out by the MSC-progeny, osteoblasts [34]. MSCs reside
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and engraft after transplant within this endosteal niche suggesting a direct interplay between
hematopoietic and skeletal homeostasis [13,35]. This has been the basis for the use of MSCs
in combination with HSC transplantation in the hopes of enhancing engraftment and
proliferation of donor HSC which is under investigation in several clinical trials [36]. As a
possible consequenc e of this tight interaction with immune cell progenitors MSCs are non-
immunogenic. This is believed to be due to low or complete lack of MHC I, II and
costimulatory molecules, meaning they can avoid activation of and clearance by the immune
system [37].
MSCs also directly modulate the immune responses of several immune cells. MSCs inhibit
the proliferation of lymphocytes, antigen presenting cells and natural killer cells, though the
mechanism is still up for debate [38]. In in vitro experiments, MSCs block activation of T
cells in response to a host of immunogenic stimuli by release of paracrine factors, though
Krampera et al. have shown a requirement for direct MSC:T cell interaction to modulate the
T cell reaction [39–41]. A diverse set of soluble factors have been proposed for this function,
including TGFβ, IGF, VEGF, HGF, IL-2, -10 and PGE2 possibly regulated by toll-like
receptors [38,41]. Indoleamine 2, 3-dioxygenase is another soluble factor released by MSCs
in response to IFNγ that depletes T cell tryptophan levels leading to inhibition of T cell
activation, proliferation and apoptosis [42]. While MSCs lack the full array of costimulatory
machinery to activate T cells, low levels of MHC-I are expressed on MSCs and IFNγ
stimulation increases MHC II molecules on the surface of MSCs. The absence of
costimulatory machinery has been associated with T cell anergy, whereby the cells become
unresponsive and unable to respond to further challenges which could also explain the
ability of MSCs to suppress the immune response [40]. Another mechanism involves MSCs
both inhibiting the maturation and inducing the reversion of mature dendritic cells to
immature cells, leading to a lack of mature antigen presenting cells and thus activated T
cells [43]. Furthermore, MSCs can decrease the release of the pro-inflammatory cytokines
TNFα and IFNγ and IL-12 produced by dendritic cells while increasing the anti-
inflammatory molecule IL-10 [44–46]. We have reported a similar effect in in vivo studies
with transplanted MSCs in a tibia fracture model in mice which lead to a decrease in the pro-
inflammatory cytokines TNFα, IL-1β and IL-6 in circulation and at the fracture site [13].
Less clear is the effect on B cells, where high volumes of MSC inhibited proliferation and
differentiation through paracrine factors in response to a B cell activating cytokine cocktail,
while MSC contact with B cells leads to increased antibody production and
proliferation [47,48]. Lastly, natural killer cell proliferation and activity are also impeded in
the presence of MSC, though this may require a combination of cell-cell contact and soluble
factors [44,49,50].
The importance of these effects was established in in vivo animal models of acute lung
injury. MSCs transplanted into mice following bleomycin-induced lung injury attenuated
tissue damage and inhibited the infiltration of neutrophils despite the low level of cell
engraftment within the lung. Instead, plasma levels of inflammatory cytokines were reduced
while lung cells produced growth factors and chemokines which were able to stimulate MSC
proliferation and migration towards injured tissue [51]. Further limiting the damage from
inflammation in MSC-transplanted mice could be the ability of MSCs to regulate the
oxidative state of the local environment. It has been proposed that MSC secrete antioxidant
molecules such as glutathione and disulfide cysteine, to maintain redox homeostasis, as seen
when conditioned media from MSCs were able to rescue oxidized cells and in an endotoxin
model of lung injury [52]. Thus, while the mechanism remains unresolved, the
immunomodulating properties of MSCs, which seem to depend on paracrine mediated
effects, are now an important factor in driving the interest of these cells for therapeutic
research.
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The initial focus for therapeutic use of MSC was on regeneration of musculoskeletal system
diseases. As the new paradigm for MSC function emerges, where the more important role is
as an initiator of healing through modulation of the initial inflammatory response and
regulation of the environmental niche through paracrine delivery of bioactive molecules that
stimulate healing, the value of developing cytokine and growth factor gene-modified MSCs,
increases. Indeed, several preclinical studies of genetically-altered MSCs have demonstrated
the enhancement of the MSC effects. This review will now summarize the current use of
gene-modified MSCs in animal models, focusing on bone related disorders.
2. Skeletal Disorders
MSCs seem tailor made to fulfill the need for novel therapies for the repair and replacement
of bone, cartilage, ligaments and tendons. In our recent studies, we have reported that MSC-
transplant improves fracture repair by improving the callus biomechanical properties and
promoting cartilage formation [13]. While these studies clearly indicate that MSCs have
beneficial effects in the healing process, the use of MSCs is far from the silver bullet first
envisioned, due to our incomplete understanding of differentiation cues and regulatory
mechanisms that trigger the regenerative response. Preclinical studies on the effect of MSCs
in fracture repair have shown promise, but also suggest that genetically manipulated MSCs
may enhance the use of MSCs in skeletal disorders.
2.1. Bone Regeneration and Repair
By far the most effort into genetically-modified MSCs has been with the BMP family of
growth factors. BMPs are members of the TGFβ superfamily of growth factors which play a
major role in the formation of bone and cartilage along with other nonosteoblastic
developmental functions [53,54]. BMP2 was discovered as a powerful bone stimulating factor
and along with other family members, such as BMP-4 and -7, have been examined as a
therapy for bone defects in several animal models [55]. BMP2 has been studied in several
clinical trials for tibial non-union fractures and has been approved for use in spinal fusion
and non-unions [56]. However, high concentrations of BMPs are required for effectiveness
which is still not always successful [57]. Using MSCs from BMP2-LacZ reporter mice we
have been able to demonstrate that transplanted MSCs improve fracture healing while
engrafting within the fracture site including a specific endosteal niche where they express
BMP2 [13]. We have also found that BMP2 expression within this niche is not driven by the
osteoblastic differentiation of MSCs. BMP2 has been reported to be necessary for the
initiation of the fracture repair process [58]. Taken together, these data indicate that MSCs
engraft within specific fracture repairing niches where they induce BMP2 which acts as a
critical initiator of the regenerative process. This suggests that combining the bone trophic
effects of BMP2 with a system to regulate the localization, temporal and levels of expression
from MSCs could be a potential target for BMP2 based therapies in non-unions.
Early experiments using BMP2 and BM stromal cells formed intramuscular ectopic bone
following implantation of adenoviral transduced cells within a femoral defect in rats [59].
The ability of BMP2-MSC to induce ectopic bone formation in immunocompromised mice
has also been shown with lentiviral vectors and the non-viral nucleofection technique [60,61].
Human MSCs, soaked into a collagen sponge, delivered BMP2 into radial fractures of
immune incompetent mice and completely bridged the gap with bone and cartilage [62]. In a
rat articular fracture model, MSCs expressing adenovirus-BMP2 (AdBMP2) induced
healing of both bone and cartilage in as little as 14 days [63]. MSCs with AdBMP2 have also
been shown to heal cranio- and maxillo-facial critical size defects in swine [64,65].
Transplant of AdBMP2-MSC into the spinal processes of rabbits induced new bone
formation and fusion with similar results in rats using adeno- or lentiviral vectors without
the need for mechanical fixation [66–69]. BMP2-MSCs also increased bone mineral density
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and content in a mouse model of osteoporosis through osteoblastic differentiation of both the
donor cells and a stimulated effect of the endogenous progenitors [70]. Taken together these
results demonstrate the enhancement of bone growth and repair when BMP2 overexpression
is combined with cells that can also respond to BMP2 signaling.
BMP2 is not the only family member with bone inducing properties. BMP4-MSCs
transplanted into the femoral BM cavity increased both trabecular and total bone density,
while the similar muscle-derived stem cells transduced with BMP4 have demonstrated
improved osteogenesis in immune competent mice [71]. BMP7 in combination with MSCs
has not been reported yet, but in periosteal cells and dermal fibroblasts, BMP7 was able to
increase intramuscular bone growth in rabbit and rat calvarial defects [72,73].
Other bone-related factors may also be effective in promoting bone growth and healing.
RunX2 is a key transcription factor in osteogenesis and can help direct cells towards
osteogenic and chondrogenic differentiation. In AdRunX2 MSCs, more bone was formed
following subcutaneous injection or transplantation into a calvarial defect in
immunecompetent mice compared to MSCs alone [74,75]. Another transcription factor, sonic
hedgehog, in adipose-derived stem cells, commonly believed to be MSCs, also increased
bone formation in a cranial defect in rabbits, though no mechanism was pursued [76]. Basic
fibroblast growth factor (bFGF) is a powerful osteogenic proliferation growth factor that
when transfected into MSC and transplanted into radial segmental defects in rabbits induced
greater bone and capillary formation, though it’s possible that the proliferation response
triggered by bFGF may ultimately inhibit the differentiation signals in progenitor
cells [77,78]. The Wnt signaling pathway has also been described as influencing
osteogenesis [79]. Wnt4-MSCs loaded on scaffolds were able to increase mineralized bone
and complete bridging of both a periodontal and calvarial defect [80]. In an attempt to
surpass telomere shortening-induced senescence of MSCs, adenoviral telomerase was used
to extend the lifespan of the cells in culture and increase ectopic bone formation and the
number of osteogenic cells after subcutaneous injection into mice [81]. LIM mineralization
protein (LMP) is a novel regulator of osteogenesis, possibly through the regulation of
osteogenic genes such as BMP2, osterix and RunX2. LMP can be spliced into 3 variants and
adenovirus-encoding LMP1 has been used in buffy coat-derived marrow cells to achieve
new bone growth and spinal fusion in rabbits, while LMP3 in the same cells, has induced
greater ectopic bone formation than AdBMP2 in skeletal muscle [82,83]. Recent work in our
laboratory has shown the positive effects of transplanted AdIGF-I-MSC in mouse tibial
fracture healing [84]. Delivery of MSCs and over expressing IGF-I at the fracture site
induced an increase in callus size and biomechanical properties over MSCs alone, or a no
cell control, due to additional bone formation [84].
In normal fracture healing, a complex milieu of growth factors and cells act in a specific
spatially and temporally regulated fashion. Current research is focused on combination
therapy with BMPs and other important osteotrophic factors to increase bone regeneration.
RunX2 may complement BMP2 signaling, as seen in vitro when AdRunX2 cells treated
with recombinant BMP2 displayed enhanced expression of osteogenic markers [85]. When
RunX2 and BMP2 were combined into an immortalized mesenchymal cell line and injected
into mice, bone and cartilage ossicles with a marrow cavity were formed to a greater extent
compared to AdBMP2 cells alone [86]. The angiogenic factor VEGF can also enhance BMP
family bone formation. When AdBMP4 and AdVEGF were co-transduced into muscle
derived stem cells and transplanted into mice, only in the presence of both factors was their
increased angiogenesis, cell survival and bone healing [87]. More recently, BMP2 and VEGF
were combined in MSCs using AAV vectors and demonstrated enhanced bone formation,
bone density and biomechanical properties following systemic administration in a mouse
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tibial defect model [88]. These results allude to the power of combinatorial gene
modifications and expand the possibilities of factors to be considered for use with MSCs.
Investigation has also begun on temporal control of growth factors in genetically-modified
MSCs. Use of regulatable vectors will allow superior control of individual factors to mimic
the intrinsic healing process and utilization of specific features of factors in combination
gene therapy, while limiting the likelihood of excess bone formation or tumorigenesis from
an unregulated cell. By using the “tet-off” system where expression of target genes can be
exogenously regulated by tetracycline treatment, Hasharoni et al. demonstrated that when
AdBMP2 was expressed by MSCs transplanted into the muscle surrounding the lumbar
spine of mice it induced a considerable amount of new bone leading to spine fusion [67]. The
“tet-on” system has also been used with BMP4 in muscle derived stem cells, a cell type
related to MSCs with a history of osteogenic potential, to demonstrate ectopic bone
formation, though in a critical-sized calvarial defect regulation was unable to halt excess
bone growth [89–91]. The “tet-off” system with RunX2 in skeletal myoblasts demonstrates
the repression in the presence, recoverability in the absence and dose-dependence of
tetracycline on the formation of ectopic bone [92].
2.2. Cartilage Repair
Cartilage damage is slow to heal due to limitation of progenitor cells and appropriate
anabolic signals. MSCs have the potential to differentiate into chondrocytes and have been
shown to slow the progression of osteoarthritis and initiate partial cartilage repair [7]. The
combination of cell transplant and gene therapy could greatly aid the cartilage repair process
by directing the differentiation and chondrogenic response of the cells. Initial gene therapy
targeting cartilage damage employed transplantation of chondrocytes transduced with
known chondrogenic stimulators IGF-I, BMP7, or FGF into rabbit and horse models of
arthritis [93–96]. In vitro, overexpression of IGF-I alone in MSCs could not induce
chondrogenic differentiation, but in concert with TGFβ1, or BMP2, induced greater
chondrogenic tissue than either alone [97,98]. This is in support of in vivo experiments where
MSCs were transfected or transduced withTGFβ1 to form ectopic cartilage in pigs, or filling
full-thickness articular cartilage defects in rabbits and rats [99–101]. AdBMP2-induced
cartilage repair was compared in adipose, BM and periosteal MSCs of rat cartilage lesions.
BM and periosteal cells showed enhanced cartilage repair compared to adipose MSCs, but
all cell types required BMP2 to initiate chondrogenesis [102]. Another member of the TGFβ
superfamily, GDF5/CDMP1 with MSCs, accelerated cartilage formation in rabbit full
thickness cartilage defects [103]. Similar to bone repair, transcription factors can be used to
regulate a host of important chondrogenic pathways. Sox9, which has been shown to
regulate a number of chondrogenic genes including collagen II, was transfected into MSCs
and transplanted subcutaneously into mice, where a collagen II-positive thick mass of tissue
formed over 4 weeks compared to untransfected cells [104]. The BMP2- and FGFR3-
regulated transcription factor Brachyury was used to force chondrogenic differentiation and
ectopic cartilage formation of a MSC-like cell line in subcutaneously injected mice [105].
More recently Sprouty1 has been postulated as a critical regulatory switch of MSC cell
lineage allocation from adipose to osteoblast progenitors [106]. These studies clearly indicate
the need to identify signaling pathways to direct stem cells to pre-determined lineages.
2.3. Ligament and Tendon Repair
The repair of ligaments and tendons using genetically-modified MSCs is a relatively new
field of study. MSCs can be forced to differentiate into tenocytes in culture and autologous
cells have been used in equine systems to repair partially damaged digital flexor
tendons [107]. Hoffmann et al. combined BMP2 signaling and Smad8 inhibition of
osteogenesis in an MSC-like cell line to form ectopic tenocytes and fill partially injured
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tendons in rats [108]. AdIGF-I-MSCs were also used in equine damaged digital flexor
tendons to induce healing of lesions, though there was no difference between empty MSCs,
suggesting some other factor may be more prominently involved [109]. Modified MSCs can
also aid in the repair of tendons indirectly. Membrane type I matrix metalloproteinase
(MT1-MMP), one of the MMPs involved in cartilage proteolysis and supporting its
mineralization, was transduced into MSCs in an attempt to improve the tendon adhesion to
the bone interface by increasing fibrocartilage formation [110]. BMP12 can induce MSCs to
differentiate into tenocytes and ligaments in vitro and in skeletal muscle cells was able to
improve healing progression and biomechanical properties of the injured rat tendon over
controls [111–113]. In a tendon allograft used to repair an ACL njury in rabbits, PDGF-B
transduced MSCs and MSCs alone were able to increase cell recruitment to the ligament but
only PDGF-B-MSCs increased angiogenesis, thus the direct contribution of MSCs versus
PDGF to this process remains to be determined [114]. A better understanding of the signaling
molecules and pathways that regulate tenocyte and ligamentogenesis will build upon these
early findings by using genetically modified MSCs.
2.4. Monogenic Bone Diseases
Hypophosphatasia is a disease characterized by reduced mineralization of the bone due to
inactivating mutations in tissue non-specific alkaline phosphatase (ALP) from osteoblasts
and chondrocytes. Transplanted MSC-differentiation into osteoblasts could be an effective
treatment for delivery of a population of cells able to produce normal ALP enzyme. Whole
BM transplants have been used to treat infants suffering from hypophosphatasia in
combination with cultured osteoblast cells, however the use of ex vivo expanded MSCs six
months after initial BM transplant yielded dramatic improvements likely due to long term
engraftment of these progenitor-supplying cells [115–117]. In all cases, despite varying
degrees of improvement, ALP levels remained low, which could be addressed by the use of
ALP-genetically-modified MSCs to deliver greater expression of the enzyme. Osteogenesis
imperfecta (OI) is a group of at least nine genetic disorders characterized by bone disease
leading to incomplete bone lengthening and increased risk of fracture with different degrees
of severity. In most affected patients, it is caused by the lack, or abnormal synthesis, of type
I collagen. The main treatment is with anti-resorptive bisphosphonates to increase bone
density, but this fails to address the underlying cause. MSCs may be useful for the treatment
of patients with OI because they can differentiate into osteoblasts and supply normal
collagen I. MSCs have already been evaluated in clinical case studies. Children with a
severe type of OI underwent BM transplant with additional MSC transplantation and
exhibited increased bone density and lengthening [118]. Allogenic MSCs were also
transplanted in utero to a female fetus, which at 9 months of age had normal growth rates
and detectable donor MSCs [119]. To test the feasibility of collagen gene targeting, MSCs
from a patient suffering from OI were transduced with a viral vector intended to target and
disrupt the mutant collagen. MSCs with successfully targeted deletion of mutant collagen
processed and formed collagen and collagen fibrils similar to wild type cells. In vivo, these
cells were able to form ectopic bone in mice [120]. This strategy would allow the use of
autologous ex vivo expanded MSC to treat OI, hypophosphatasia and possibly other bone
monogenic diseases.
3. Cardiovascular and Ischemic Disease
In the last decade, there has been an escalation of studies involving MSCs and
cardiovascular disease. Specifically in myocardial infarctions, the plasticity, homing and
inflammatory modulation of MSCs are all important properties that come into play
following the hypoxia-induced damage to cardiomyocytes due to occluded arteries. The
myocardium lacks the ability to efficiently replace these cells, and thus the goal of any
treatment is the replacement of cardiomyocytes. Several studies have shown the ability of
Myers et al. Page 8













MSCs to transdifferentiate into cardiomyocytes in vitro and in animal models of myocardial
infarction, though there is also evidence that the number of stem cells that engraft and
differentiate into cardiomyocytes is extremely low [121]. Still, clinical trials for the use of
MSCs to treat acute myocardial infarctionare under way with promising results [122]. The
use of genetically-modified MSCs in these animal models attempts to improve the homing,
survival and paracrine-mediated effects of MSCs. Systemically infused CXCR4-
overexpressing MSCs are more abundant in and around the infarcted area in rat hearts and
led to improved function compared to MSCs alone [23,123,124]. Similar results were seen
with the chemokine receptor CCR1 [125]. In rodent models of myocardial infarction, besides
increased homing to the injury, CXCR4- and SDF1-modified MSCs expressed increased
amounts of angiogenic and growth factors, improved endothelial differentiation and
angiogenesis leading to improved cardiac function [123,126].
Most other studies have aimed to improve MSC survival following transplantation. A major
cause of cell death in the infarcted heart is due to the low oxygen content. To enhance the
ability of MSCs to tolerate the hypoxic conditions, MSCs were modified with the hypoxic-
regulated, anti-apoptotic proteins heme oxygenase-1 or angiogenin, which is also a
protective and angiogenic molecule, resulting in increased cell survival, signs of
neoangiogenesis and improved heart function [127–129]. TNFα receptor is a mediator of
inflammation in ischemic heart but may have survival effects for MSCs as seen with TNFα
receptor overexpressing-MSCs in a rat model of acute myocardial infarction and supported
by the loss of cardioprotective effects in mice transplanted with TNFα receptor-2 knockout
MSCs [130,131]. Other anti-apoptotic molecules such as Bcl2, survivin, adrenomedullin, and
erythropoietin have all induced increased survival of transplanted cells within the infarcted
area and increased angiogenesis as measured by capillary density [132–135]. IGF-I is a potent
proliferative and differentiative factor for MSCs and when expressed by MSCs in the
context of a coronary artery occlusion, induced expression of anti-apoptotic factors such as
Bcl.xL and the homing factor SDF1 which in turn led to an increase in the number stem
cells around the blockage [136]. Transplant of MSCs modified to express VEGF under
hypoxic conditions increased MSC cell survival, differentiation into cardiomyocytes, induce
angiogenesis and improve overall heart function [137]. HGF transduced into MSCs had
similar effects to VEGF-MSCs, while SDF1-VEGF-MSCs were superior to either single
transduced MSCs in augmenting survival of MSCs, shrinking infarct sizes and increasing
vascular density, possibly dependent on the Akt pathway to moderate the effects [126,138].
The direct effects of Akt1 expressed in transplanted MSC have also been evaluated. This
prosurvival protein in MSCs dose-dependently increased myocardial volume and heart
function in a heart ischemia model despite low engraftment and differentiation of
MSCs [139]. Akt1 actions were dependent on an increase in the secreted frizzled related
protein 2 and its subsequent paracrine activation of Wnt signaling in endogenous cells that
then normalized cell metabolism and environment [140,141]. The angiogenic factor
angiopoietin-1 alone or in collaboration with Akt1 in MSCs also improve vascular density
and heart function [142,143]. Lastly, Song et al. were able to increase the survival rate of
MSCs transplanted into infarcted heart by transducing cells with integrin-linked inase which
amplified expression of anti-apoptotic genes and proliferative signaling to improve heart
function, presumably due to increased adhesion of the cells within the damaged tissue [144].
Along with ischemic heart, other organs are also sensitive to MSC treatment in response to
the hypoxic conditions following ischemia/reperfusion. MSC transplant into rodent models
of renal, limb, lung and brain ischemia has shown beneficial effects. Much of the genetic
modifications used with MSCs in these models have focused on protecting the cells from the
hypoxic conditions along with stimulating neoangiogenesis. In rodent models of hindlimb
ischemia, transplanted MSCs modified to express VEGF or angiopoietin-1, increased vessel
density as early as 14 days post injury/transplant and demonstrated enhanced MSC survival
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within the damaged tissue [145,146]. Interestingly, VEGF was transfected into MSCs using
polymeric nanoparticles that avoid potential safety concerns of the generally used viral
delivery systems [145]. Angiopoietin-1-MSCs were studied in a lung ischemia model which
limited damage and scarring by inhibiting the recruitment of inflammatory cells [147].
Likewise, the anti-inflammatory cytokine IL-10, delivered to ischemic lung tissue in rats by
genetically engineered MSCs, inhibited inflammatory cell infiltration, decreased damage to
lung tissue and increased lung function over MSCs alone [148]. MSCs have also been used to
prevent lung ischemia by preventing pulmonary hypertension. Prostacyclin synthase and
eNOS expressing-MSCs transplanted into rats with monocrotalin-induced pulmonary
hypertension, with the goal of expanding the lung arteries, eased the strain on the heart and
extended the survival time of the animals [149,150]. MSCs can protect against acute kidney
failure which have lead to more recent experiments to enhance this effect [151]. Kallikrein is
a renoprotective molecule due its anti-inflammatory, -apoptotic and -dilation activities.
When delivered to kidneys of rats in a renal ischemia/reperfusion injury model by modified
MSCs caused a decrease in blood urea nitrogen and creatine levels and the number of
apoptotic kidney cells and inflammatory cells within the kidney [152]. While these studies
demonstrate the various and numerous potential factors for the enhancement of MSC-
dependent treatment of acute myocardial infarctions and other ischemic injuries, it seems
likely the best approach will be a combination of molecules that target the cells
appropriately and regulate both the paracrine stimulation of surrounding cells and the
differentiation of the transplanted MSCs.
4. Cancer
Targeting solid tumors with anti-tumor gene therapy has been hindered by systemic toxicity,
low efficiency of delivery and nominal temporal expression. Cell-based targeting with
MSCs has recently been utilized to overcome these issues. MSCs are capable of
preferentially homing to sites of primary and metastatic tumor growth and delivering anti-
tumor agents to highly specific niches surrounding the tumors. The two main categories for
gene targeting are cytotoxic, or pro-apoptotic genes, and immunostimulatory genes.
Receptors for the pro-apoptotic gene TNF-related apoptosis inducing ligand are expressed
on many types of tumors and when soluble forms of the ligand are expressed in MSCs, and
properly localized in xenograft mouse models of human cervical and breast cancers and
gliomas, have caused the decrease in proliferation and tumor size and increased apoptosis
and survival time [153–157]. Inducible nitric oxide synthase has also been shown to be
potentially powerful anti-tumor therapy that when delivered to a fibrosarcoma model in
mice by genetically-modified MSCs reduced tumor growth [158]. Replication competent
viruses that target cancer cells are another means to eliminate tumors. Once the virus has
replicated within the cancer cells the cell is lysed to release the virus. Due to toxicity to
normal cells, targeting and delivery are especially important. MSCs carrying engineered
adenoviruses have been used to target ovarian, breast, lung and brain tumors leading to
decreased tumor burdens and increased survival times [159–163]. MSC-based gene therapy
can also increase the usefulness of current anti-cancer therapies. A combination of
genetically-modified MSCs to deliver cytosine deaminase and treatment with the less toxic
prodrug 5-fluorocytosine, which is converted to 5-fluorouracil by cytosine deaminase within
the MSC-containing tumor niche, could replace systemic delivery of the highly toxic 5FU as
demonstrated in mouse models for colon, prostate and skin cancers [164–166]. MSCs
delivering the suicide gene herpes simplex virus thymidine kinase, in combination with
ganciclovir treatment to produce tumor-localized toxic metabolites to surrounding cells, has
shown promising results in rodent xenograft models of human pancreatic carcinomas and
gliomas [167,168].
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The second class of therapeutic transgenes is immunomodulatory targets. MSCs engineered
to express IL-2, -7, -12 and -18 have decreased tumor size in rodent xenograft models of
primary, established and metastatic tumors [169–175]. MSCs bearing other immune cytokines
such as IFN-α and –β and CX3CL1/fractalkine increase tumor cell apoptosis and animal
survival times in prostate, lung, pancreatic and skin cancers through activation of innate
immune activity such as natural killer cells, or adaptive immune response through increased
activation of T cells [176–180]. Other emerging transgenes for tumor therapy combined with
MSCs are anti-angiogenic factors such as soluble VEGF receptor, a urokinase-type
plasminogen pathway antagonist, amino terminal fragment, and the HGF pathway
antagonist NK4 which inhibited tumor growth and increased survival time in xenograft
mouse models of lung tumors, lymphoma and bone metastasized prostate cancer [181–183].
While initial animal studies are promising, there are still issues to be addressed. Some
evidence exists that the location of the injection may affect the efficacy of the genetically-
modified MSCs, thus further studies are required to determine whether systemic versus local
injection is optimal [184]. More directly, the properties that make MSCs attractive as a
therapeutic vector may in fact facilitate tumor growth [184,185]. The immunosuppressive
effects of MSCs could disable the intrinsic antitumor immune response as when a
subcutaneous injection of melanoma cells in mice only formed tumors when co-injected
with MSCs, presumably due to modulation of the immune system [186]. In this model MSCs
were localized to the stromal periphery of the tumor suggesting that MSCs may also affect
the tumor niche by adding structural support for tumor proliferation by differentiation into
fibroblasts [187]. Tumor support and growth could also be supplemented by release of
trophic factors from MSCs. Several examples of the angiogenic effects of MSCs have been
presented above and VEGF from MSCs aided in the growth of Burkitt’s lymphoma cells,
while secretion of chemokines could promote tumor metastasis [183,188]. Lastly, the
unlimited potential for proliferation could also lead to transformation of MSCs into
malignant tissue. Long term passaging may lead to chromosomal abnormalities, though
current data suggests that human MSCs are not susceptible to transformation [189,190]. Thus,
while the role of MSCs in tumor proliferation remains unresolved, these concerns need to be
addressed before MSC-based anti-tumor gene therapy becomes a realistic possibility.
5. Conclusion
These preclinical animal studies of genetically-modified MSCs reveal the possibilities for
clinical application with the potential for wider applications. Exciting new research into
repair of the nervous system with MSCs engineered to express brain-derived neurotrophic
factor or other neural growth factors could have implications for the regeneration of neurons
following stroke, spinal injury or genetic neurological disorders, while recapitulation of
pancreatic cells using pancreatic and duodenal homeobox-1-MSCs could restore insulin
producing islet cells to diabetic patients [191–198]. Other MSC-based therapies that do not
involve genetic engineering, especially the use of MSCs to improve BM and solid organ
transplants, are further along, as evidenced by the number of clinical trials using MSCs
compared to genetically-engineered MSCs [199]. This is due to the fundamental concerns
facing the use of both MSCs and the gene therapy. For MSCs, identifying a standardized
tissue and donor source, isolation and expansion procedures, definition of markers to
improve homogeneity of MSCs, dosing and administration site will affect the safety and
efficacy of cell therapy. The safety concerns facing gene therapy are much more daunting.
The transfer of genetic material is still most efficiently conducted using the viral vectors:
adenovirus, adeno-associated virus, retroviruses or lentiviruses. Each has advantages, but the
concerns of an immune response outweigh the risk in all but the most dire of cases.
Refinement and design of novel, non-viral delivery methods for naked or plasmid DNA,
such as the use of lipids or nanoparticles, will reduce the likelihood of an immune response
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and limit incorporation of DNA into the genome [145,200]. Use of regulatable gene systems
will allow precise control over temporal expression patterns to eliminate the issues of over-
or under-dosing during the repair process. There remains much work to be done, but by
utilizing the inherent properties of MSCs and improved gene delivery, we are entering an
exciting new era where the use of genetic engineering therapies will be safe, efficient and
efficacious.
6. Expert Opinion
The increasing interest and research employing MSCs to treat a myriad of diseases justifies
the early expectations of these cells. There are now nearly 150 clinical trials targeting
skeletal and cardiac problems to transplants and graft versus host disease, diabetes and
multiple sclerosis, all utilizing unmodified MSCs [199]. These studies will provide critical
information on the safety profile and efficacy of MSCs. We envision that future MSC-based
therapies will employ genetically programmed cells to enhance the natural effects of MSCs.
By utilizing cell therapy techniques, gene therapy will be propelled into a new era. The
characteristics and properties described throughout this review, in our opinion, make MSCs
the most promising and viable vector for the delivery of genetic therapies. They have none
of the ethical concerns of embryonic stem cells, are expandable and are more efficient in
accepting non-viral gene transfer, such as lipid or nanoparticle-based methods. These
combined with their apparent natural healing properties, such as the ability to modulate the
immune system, home to injured tissue, regulate angiogenesis and possibly incorporate into
surrounding tissue following differentiation, advocate for the continued work in
understanding MSC biology. Discoveries of MSC-pathways and cell-cell interactions may
lead to MSC-based targeted gene therapy.
While solving the mechanistic questions surrounding MSCs would surely aid in harnessing
their unique capabilities, some of the more pressing issues facing the use of MSCs is the
handling of these cells. A lack of a standardized protocol for culturing and expanding MSCs
has led to three main concerns. First, it seems apparent now that long-term culture increases
heterogeneity of the cell population. An increasingly diverse population of cells makes it
hard to clearly define the functional population and the mechanisms responsible for any
detectable effect. This could also explain the loss of efficient MSC engraftment along with
differences between results from individual laboratories and clinical trials that have led to
controversy. Thus, the identification of markers is a critical need to truly define MSCs and
to identify and track the progeny of these cells, similar to the highly organized and
comprehendible lineage of HSC. Secondly, long-term culturing can also lead to down
regulation of functional surface proteins, such as CXCR4 and long-term ex vivo expanded
cells show reduced migration and homing potential in vivo [201,202]. This has caused
problems when attempting to transfer results from the bench to the bedside as cell behavior
can be drastically different depending on the methods employed by various laboratories.
Finally, along with concerns of serum-dependent growth for transplant into humans,
cultured MSCs can acquire mutations and become transformative as in the case with the
formations of sarcomas from transplanted MSCs in mice [203]. Several laboratories have
endeavored to optimize the growth conditions for various sources of MSCs, but ultimately it
will require a consensus among the leaders of the field and a commitment across all
laboratories before consistent and reproducible results will yield a complete understanding
of MSC biology.
Along with handling these cells, it is important to consider the source used to isolate and
expand MSCs. There are reports describing the isolation of MSCs from peripheral blood and
many different tissues. Most effort on MSCs has been with BM derived cells, but
increasingly from adipose tissue and umbilical cord blood. Mostly cells from divergent
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sources are more similar than different, yet inherently tend to favor the tissue type from
which they were harvested and can lead to transplanted cells engrafting in these niches
instead of their intended target. This implies that the microenvironment where MSCs reside,
whether it is perivascular, in the BM or some yet to be defined area, has a substantial effect
on the homing, differentiative and regenerative capabilities of MSCs even after isolation.
The surrounding cells and extracellular milieu also seems to influence the surface proteins
and epitopes which would be used as identifying markers [204]. Defining the interaction of
MSCs within its natural environment will be crucial to understanding the molecular cues
that maintain MSC stemness, influence migration and drive proliferation versus
differentiation decisions and thus our ability to fully harness the potential of MSCs for cell
based therapies. Identifying the natural niche could also lead to a better understanding of the
surface proteome of MSCs and possibly to the discovery of a common MSC progenitor and
its markers for identification and progeny-tracking. Embryonic studies indicate that MSCs,
along with other adult stem cell lines, derive from epiblast stem cell progeny primordial
germ cells (PGC) [205] and PGC-like cells have been found in the adult bone marrow [206].
Further studies are required to confirm that these are truly postnatal MSC progenitors, to
determine the origin niche and whether the embryonic niche is the same as the natural adult
niche, but this is a promising area of research for the identification of a MSC niche.
However, until then, it is our opinion that the therapeutic application of MSCs should be
based on their source-niche to benefit from the influence of this microenvironment on the
differentiation fate of MSCs.
To summarize, we propose that the identification of the natural niche and engrafting niche
for MSCs after transplant is the key for unlocking the untapped potential of MSC-based
therapeutics (Fig. 1). By identifying the natural niche, we gain a better understanding of the
basic biology that influences fate decisions of the common progenitor (Fig. 1A) and the
prospective differences in MSCs from various adult niches. This knowledge will lead to
better targeting of transplanted MSCs to distinct engraftment niches (Fig. 1B). This would
also allow for identification of markers and the eventual conformity in ex vivo culturing
procedures for MSCs (Fig. 1C). A better understanding of MSC biology would also lead to
better choices in genes for enhancing the intrinsic MSC characteristics that make them
valuable as a therapeutic option (Fig. 1C and D). Applying what we have learned will result
in favorable conditions to employ genetically-modified MSCs for monogenic as well as
multigenic diseases (Fig. 1E).
Article Highlights
• Introduction: Multipotent stromal cells can be used to treat a wide range of
diseases by harnessing the best of both cell and gene therapy characteristics.
• Skeletal disorders: MSCs can deliver immunomodulatory, anti-inflammatory,
bone stimulating and angiogenic factors to initiate healing, promote
differentiation of self and intrinsic cells to repair and form new bone.
• Cardiovascular and Ischemia: MSCs can home to sites of vascular injury to
initiate healing, supply angiogenic and anti-inflammatory effects.
• Cancer: MSCs can home to sites of cancerous growth to deliver cytolytic or
apoptotic-inducing factors.
• Conclusion: MSCs have a great potential for clinical applications though hurdles
remain before the clinical use of MSCs-based gene therapy is implemented.
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• Expert Opinion: A greater understanding of MSC biology, identification of the
natural and engrafting niche for MSCs and a consensus for how to culture and
expand MSCs will lead to quicker implementation of MSC-based therapies.
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MSCs from niche to bedside. A) Homogenous, pure MSCs would be isolated from their
natural niche to be utilized for therapeutic purposes. B) These MSC progenitors give rise to
tissue-specific heterogeneous populations of MSCs from bone marrow, adipose tissue
perivascular regions and umbilical cord blood that can also be used as a therapeutic
treatment. C) Ex vivo expanded cells could then be expanded and modified by gene transfer
with appropriate genes to enhance D) the chemokine homing, functional niche engraftment,
establishment of a healing microenvironment, modulation of the immune system, release of
bioactive paracrine factors and differentiation into functional tissue E) for use in treatment
of monogenic diseases, such as OI or hypophosphatasia, or more complex multigenic
diseases.
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